ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company specializing in central nervous system (CNS) disorders, is navigating a critical phase of growth and expansion. With a robust ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) ...

SAN DIEGO, July 03, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted ...

Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8 ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards ...

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...